Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-12-17 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团第十届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 30th meeting of the 10th Board of Directors of the company. It details voting results on specific proposals related to investments, guarantees, and capital expenditures by subsidiaries. There is no financial data, no mention of annual or quarterly reports, no audit information, and no presentation materials. The content focuses on board decisions and approvals, which aligns with announcements about board or management matters. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear alignment with board meeting resolutions.
2024-12-17 Chinese
健民集团关于对子公司银行授信额度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by the company regarding the provision of a guarantee for a bank credit facility extended to its wholly-owned subsidiary. It details the guarantee amount, the terms, the internal approval process, and the financial status of the subsidiary. There is no financial statement or comprehensive financial report included. The document is an announcement of a financing-related guarantee, not a full capital or financing update report. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2024-12-17 Chinese
健民集团2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of the company. It includes details about the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2024-12-12 Chinese
湖北得伟君尚律师事务所关于健民药业集团股份有限公司2024年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of a company's 2024 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting's process and voting results. It does not contain financial statements, management discussion, or earnings data. It is not a report of voting results but a legal opinion on the meeting's conduct. The document length is short (2136 characters), and it is not an announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS) as a legal compliance document related to shareholder meetings.
2024-12-12 Chinese
健民集团2024年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2024 Second Extraordinary General Meeting" of the company, including the meeting agenda, voting procedures, and a specific proposal to amend the company's articles of association. It details the meeting logistics, voting methods, and the resolution to be voted on. There is no financial data, earnings information, or audit content. The document is clearly a set of meeting materials for a shareholders' meeting, not the meeting minutes or voting results. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is 2248 characters, which is consistent with meeting materials rather than a full report or announcement of results. Therefore, the classification is AGM-R with high confidence.
2024-12-06 Chinese
关于公司产品新进入及续约《国家医保目录（2024年）》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion and renewal of its pharmaceutical products in the National Medical Insurance Catalog for 2024. It provides details about the products, their approval status, sales figures, and the impact on the company. There is no financial report, earnings data, or management discussion of financial results. The document is an official announcement about product listing and related policy updates, not a financial report or regulatory filing. It is a regulatory announcement informing shareholders and the market about product catalog inclusion and its implications. Given the nature and length of the document, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-11-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.